LNTH Quote, Financials, Valuation and Earnings

Electromed has a net margin of 19.57% compared to Lantheus Holdings's net margin of 12.06%. Lantheus Holdings's return on equity of 23.53% beat Electromed's return on equity of 16.57%.

Lantheus Holdings has a consensus price target of $128.31, signalling upside risk potential of 62.03%. On the other hand Electromed has an analysts' consensus of $38.00 which suggests that it could grow by 85.1%. Given that Electromed has higher upside potential than Lantheus Holdings, analysts believe Electromed is more attractive than Lantheus Holdings.

Lantheus Holdings has a beta of 0.106, which suggesting that the stock is 89.373% less volatile than S&P 500. In comparison Electromed has a beta of 0.398, suggesting its less volatile than the S&P 500 by 60.159%.

Lantheus Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lantheus Holdings pays -- of its earnings as a dividend. Electromed pays out -- of its earnings as a dividend.

Lantheus Holdings quarterly revenues are $372.8M, which are larger than Electromed quarterly revenues of $15.7M. Lantheus Holdings's net income of $72.9M is higher than Electromed's net income of $1.9M. Notably, Lantheus Holdings's price-to-earnings ratio is 22.50x while Electromed's PE ratio is 25.99x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lantheus Holdings is 3.71x versus 3.00x for Electromed. Usually stocks with elevated PS ratios are considered overvalued.

Integra Lifesciences Holdings has a net margin of 19.57% compared to Lantheus Holdings's net margin of -6.61%. Lantheus Holdings's return on equity of 23.53% beat Integra Lifesciences Holdings's return on equity of -1.88%.

Lantheus Holdings has a consensus price target of $128.31, signalling upside risk potential of 62.03%. On the other hand Integra Lifesciences Holdings has an analysts' consensus of $16.13 which suggests that it could grow by 39.01%. Given that Lantheus Holdings has higher upside potential than Integra Lifesciences Holdings, analysts believe Lantheus Holdings is more attractive than Integra Lifesciences Holdings.

Lantheus Holdings has a beta of 0.106, which suggesting that the stock is 89.373% less volatile than S&P 500. In comparison Integra Lifesciences Holdings has a beta of 1.164, suggesting its more volatile than the S&P 500 by 16.396%.

Lantheus Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Integra Lifesciences Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lantheus Holdings pays -- of its earnings as a dividend. Integra Lifesciences Holdings pays out -- of its earnings as a dividend.

Lantheus Holdings quarterly revenues are $372.8M, which are smaller than Integra Lifesciences Holdings quarterly revenues of $382.7M. Lantheus Holdings's net income of $72.9M is higher than Integra Lifesciences Holdings's net income of -$25.3M. Notably, Lantheus Holdings's price-to-earnings ratio is 22.50x while Integra Lifesciences Holdings's PE ratio is 70.14x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lantheus Holdings is 3.71x versus 0.55x for Integra Lifesciences Holdings. Usually stocks with elevated PS ratios are considered overvalued.

VolitionRX has a net margin of 19.57% compared to Lantheus Holdings's net margin of -2201.34%. Lantheus Holdings's return on equity of 23.53% beat VolitionRX's return on equity of --.

Lantheus Holdings has a consensus price target of $128.31, signalling upside risk potential of 62.03%. On the other hand VolitionRX has an analysts' consensus of $2.93 which suggests that it could grow by 219.57%. Given that VolitionRX has higher upside potential than Lantheus Holdings, analysts believe VolitionRX is more attractive than Lantheus Holdings.

Lantheus Holdings has a beta of 0.106, which suggesting that the stock is 89.373% less volatile than S&P 500. In comparison VolitionRX has a beta of 1.072, suggesting its more volatile than the S&P 500 by 7.247%.

Lantheus Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lantheus Holdings pays -- of its earnings as a dividend. VolitionRX pays out -- of its earnings as a dividend.

Lantheus Holdings quarterly revenues are $372.8M, which are larger than VolitionRX quarterly revenues of $246.4K. Lantheus Holdings's net income of $72.9M is higher than VolitionRX's net income of -$5.4M. Notably, Lantheus Holdings's price-to-earnings ratio is 22.50x while VolitionRX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lantheus Holdings is 3.71x versus 63.41x for VolitionRX. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of 19.57% compared to Lantheus Holdings's net margin of 0.18%. Lantheus Holdings's return on equity of 23.53% beat Xtant Medical Holdings's return on equity of -26.62%.

Lantheus Holdings has a consensus price target of $128.31, signalling upside risk potential of 62.03%. On the other hand Xtant Medical Holdings has an analysts' consensus of $1.75 which suggests that it could grow by 192.15%. Given that Xtant Medical Holdings has higher upside potential than Lantheus Holdings, analysts believe Xtant Medical Holdings is more attractive than Lantheus Holdings.

Lantheus Holdings has a beta of 0.106, which suggesting that the stock is 89.373% less volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of -0.181, suggesting its less volatile than the S&P 500 by 118.091%.

Lantheus Holdings has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Lantheus Holdings pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

Lantheus Holdings quarterly revenues are $372.8M, which are larger than Xtant Medical Holdings quarterly revenues of $32.9M. Lantheus Holdings's net income of $72.9M is higher than Xtant Medical Holdings's net income of $58K. Notably, Lantheus Holdings's price-to-earnings ratio is 22.50x while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Lantheus Holdings is 3.71x versus 0.67x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.